Relmada Corp - Rega Nyata Tumbas Perusahaan Kanthi Wutuh RLMD

The market price for Relmada Therapeutics (RLMD) on the GURU.Markets platform, as confirmed by this chart, is 124.68. The business relies on US laboratories, while drug development is outsourced to external CDMO facilities. Relmada Therapeutics occupies a niche segment in the treatment of major depressive disorder, yet faces the threat of share devaluation and financial losses due to the risks of failure in the final trials of its lead drug candidate.

Investors assess the enterprise value to stress-test assets. Relmada Therapeutics (RLMD) is currently in the clinical trial stage without stable sales. This market price indicator, adjusted for debt, sums the market capitalization and liabilities while subtracting cash and cash equivalents. This methodology determines the actual cost of a full buyout of the issuer. For this specific business model, the metric reflects the cost of raised capital.